|1.||Mondal, Indrani: 3 articles (10/2015 - 10/2014)|
|2.||Chiou, Shih-Hwa: 3 articles (05/2012 - 11/2010)|
|3.||Chen, Yi-Wei: 3 articles (05/2012 - 11/2010)|
|4.||Huang, Pin-I: 3 articles (05/2012 - 11/2010)|
|5.||Tseng, Ling-Ming: 3 articles (05/2012 - 11/2010)|
|6.||Chen, Yu-Chih: 3 articles (05/2012 - 11/2010)|
|7.||Lai, Raymond: 3 articles (04/2010 - 10/2006)|
|8.||Lavasanifar, Afsaneh: 3 articles (04/2010 - 01/2006)|
|9.||Molavi, Ommoleila: 3 articles (04/2010 - 01/2006)|
|10.||Samuel, John: 3 articles (04/2010 - 01/2006)|
07/01/2011 - "It is noteworthy that 150 nM cucurbitacin I effectively blocked STAT3 signaling and downstream survival targets, such as B-cell chronic lymphocytic leukemia/lymphoma 2 (Bcl-2) and Bcl-2-like 1 (Bcl-xL) expression and induced apoptosis in CD133-positive NSCLC cells. "
10/01/2015 - "Doxorubicin resistant Dalton's lymphoma responds to therapy with high doses of cucurbitacin-I and rIL-15. "
10/01/2015 - "The combined treatment of low dose of cucurbitacin-I and rIL-15 is ineffective in mice with doxorubicin resistant Dalton's lymphoma, but a similar therapy prolongs the survival of mice transplanted with parental Dalton's lymphoma. "
10/01/2015 - "Doxorubicin resistant Dalton's lymphoma is susceptible to dendritic cell derived TNF-α upon stimulation with the STAT3 inhibitor cucurbitacin-I, which downregulates STAT3 and other survival molecules. "
05/01/2015 - "Combined immunotherapy with whole tumor lysate-pulsed interleukin-15-activated dendritic cells and cucurbitacin I promotes strong CD8(+) T-cell responses and cures highly aggressive lymphoma."
|2.||Cardiomegaly (Heart Hypertrophy)
01/01/2015 - "Taken together, these findings signify that cucurbitacin I protects the heart against cardiac hypertrophy via inhibition of CTGF/MAPK, and TGF- β/Smad-facilitated events. "
01/01/2015 - "Accordingly, the present study provides new insights into the defensive capacity of cucurbitacin I against cardiac hypertrophy, and further suggesting cucurbitacin I's utility as a novel therapeutic agent for the management of heart diseases. "
01/01/2015 - "To evaluate the functional role of cucurbitacin I in an in vitro model of cardiac hypertrophy, phenylephrine (PE)-stimulated cardiomyocytes were treated with a sub-cytotoxic concentration of the compound, and the effects on cell size and mRNA expression levels of ANF and β-MHC were investigated. "
|3.||Heart Diseases (Heart Disease)
|4.||Neoplasm Metastasis (Metastasis)
04/11/2014 - "Current studies have suggested that cucurbitacin I, a natural selective inhibitor of JAK2/STAT3, has a potent anticancer effect on a variety of cancer cell types. "
05/01/2015 - "Therapy with tumor lysate-pulsed, rIL-15-activated DCs plus cucurbitacin I significantly prolongs the survival of tumor-bearing mice but fails to provide a complete cure. "
02/01/2015 - "Cucurbitacin-I warrants further investigation as an angiogenesis inhibitor for use in cancer treatment."
02/01/2015 - "Cucurbitacin-I is a naturally occurring tetracyclic triterpenoid compound with diverse physiological actions that include inducing apoptosis and blocking cell cycle progression of various cancer cells. "
01/01/2015 - "In this work, we used JSI-124 (Cucurbitacin I), a selective JAK/STAT3 signaling pathway inhibitor, to investigate the role of STAT3 in tumor angiogenesis of a human BC cell line in vitro. "
|1.||Interleukin-15 (Interleukin 15)
|3.||aldehyde dehydrogenase 1
|4.||AC133 antigen (prominin)
|5.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|7.||DNA (Deoxyribonucleic Acid)
|8.||Connective Tissue Growth Factor
|9.||AMP-Activated Protein Kinases
|3.||Tissue Therapy (Cell Therapy)